Clinical trials: Pancreatic Cancer Borderline
Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline
EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer
This is an open label phase II study to determine the safety and preliminary efficacy of photoimmunotherapy (PIT) for patients with locally advanced and borderline resectable pancreatic cancer.
- Conditions
- Pancreatic Cancer Patients Diagnosed With Locally Advanced or Metastatic Pancreatic Cancer Not Amenable to Curative Surgical Resection, Pancreatic Cancer Borderline, Pancreatic Cancer Resectable
- Trial name
- NCT07698613
- Testing
- ASP-1929 photoimmunotherapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Brown University
Pancreatic Cancer
Combination of Anti-PD-1 Antibody and Chemotherapy in Pancreatic Cancer
The prognosis of pancreatic cancer is extremely poor. Current guidelines recommend FOLFIRINOX or modified-FOLFIRINOX as the first-line chemotherapeutic regimen.
- Trial name
- NCT03983057
- Testing
- Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Zhejiang University
Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer
Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.
Pancreatic ductal adenocarcinoma (PDAC) remains a dreadful disease due to its often advanced stage at diagnosis and poor sensitivity to chemotherapy.
- Trial name
- LAPTOP (NCT04247165)
- Testing
- Gemcitabine, Nab-paclitaxel, Nivolumab
- Where
- Denmark
- Volunteers
- 55 people
- Sponsor
- Herlev Hospital
Locally Advanced Unresectable Pancreatic Cancer Treated With Chemoradiotherapy, Borderline Resectable Pancreatic Cancer Treated With Chemoradiotherapy
A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
The investigators hypothesize that intensification of local therapy will lead to improvements in local control and survival in patients with unresectable and borderline resectable pancreatic cancer.
- Trial name
- NCT02207465
- Testing
- Radiotherapy, Abraxane
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Pancreatic Cancer
AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.
The goal of this interventional study is to learn about the clinical efficacy of sequential therapy (albumin paclitaxel, gemcitabine combined with PD-L1 antibodies, followed by liposomal irinotecan, oxaliplatin and 5-FU/LV…
- Trial name
- ZSPAC-14 (NCT07208539)
- Testing
- Treatment: AG & anti-PD-L1 + FOLFIRINOX & anti-PD-L1
- Volunteers
- 77 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
The goal of this study is to learn if the genetic information and proteins from tumours can help treat pancreatic ductal adenocarcinoma (PDAC).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- ACCELERATE (NCT06574620)
- Testing
- Genetic testing, Optional biopsy, Tissue collection
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- British Columbia Cancer Agency
Pancreatic Cancer
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Treating patients with initial local non-resectable pancreatic cancer with a combination of oxaliplatin, irinotecan \& 5-FU(FOLFIRINOX), consolidated with chemoradiotherapy in potentially resectable patients, will result in a…
- Trial name
- NCT01397019
- Testing
- Oxaliplatin, irinotecan, 5-FU & leucovorin
- Where
- 3 sites in Denmark
- Volunteers
- 56 people
- Sponsor
- Per Pfeiffer
Periampullary Cancer, Borderline Malignancy Tumor
The Effect of ERAS on Pancreaticoduodenectomy (v2.0)
Enhanced Recovery After Surgery (ERAS) is not a program that aims to reduce postoperative hospital stay, but the multimodal strategies that aim to attenuate the loss of, and improve the restoration of, functional capacity after…
- Trial name
- NCT06009224
- Testing
- ERAS perioperative management
- Where
- South Korea
- Volunteers
- 334 people
- Sponsor
- Asan Medical Center
Pancreatic Neoplasms
Neoadjuvant Gemcitabine, Docetaxel, and Capecitabine in Combination With Stereotactic Radiosurgery
The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at the patient's tumor followed by more…
- Trial name
- NCT00833859
- Testing
- GTX (gemcitabine, docetaxel and capecitabine), stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer
- Trial name
- NCT06673017
- Testing
- PTM-101
- Where
- 9 sites in United States, Australia
- Volunteers
- 26 people
- Sponsor
- PanTher Therapeutics
Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
This phase II trial studies how well combination chemotherapy, gemcitabine hydrochloride, and radiation therapy before surgery works in treating patients with pancreatic cancer that has not spread to other places in the body and…
- Conditions
- Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01897454
- Testing
- Fluorouracil, Gemcitabine Hydrochloride, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Albert Einstein College of Medicine
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer
The goal of this prospective observational study is to learn about the clinical utility of dynamic ctDNA-based Minimal Residual Disease (MRD) monitoring in patients with borderline resectable pancreatic cancer undergoing…
- Trial name
- MRD (NCT07080021)
- Testing
- Standard Reagents, Pancreatic Cancer
- Where
- 2 sites in China
- Volunteers
- 119 people
- Sponsor
- Ruijin Hospital
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
This phase II trial studies how well nab-paclitaxel and gemcitabine hydrochloride followed by radiation therapy before surgery work in treating patients with pancreatic cancer that can be removed by surgery.
- Trial name
- NCT02427841
- Testing
- Fluorouracil, Gemcitabine, Image Guided Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- OHSU Knight Cancer Institute
Pancreatic Cancer, Adult
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer
This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. Led by The First Affiliated Hospital with Nanjing Medical University and Peking University Cancer Hospital \& Institute (as leading centers)…
- Trial name
- NOTABLE-309 (NCT07277452)
- Testing
- Nimotuzumab, AG regimen
- Where
- 2 sites in China
- Volunteers
- 156 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
This pilot and feasibility study studies how well nivolumab and combination chemotherapy work before surgery in treating patients with pancreatic cancer that could possibly be removed by surgery.
- Trial name
- NCT03970252
- Testing
- Fluorouracil, Irinotecan, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Patients With Borderline Resectable Pancreatic Cancer
Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study
FOLFIRINOX regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer.
- Trial name
- FIRINOX (NCT02148549)
- Testing
- FIRINOX
- Where
- 9 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Wakayama Medical University
Pancreatic Cancer
Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to…
- Trial name
- NCT03621644
- Testing
- Stereotactic MRI-guided On-table Adaptive Radiation Therapy
- Where
- 13 sites in United States, Israel
- Volunteers
- 133 people
- Sponsor
- Viewray Inc.
Pancreatic Cancer
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
Phase II study of neoadjuvant treatment with Gemcitabine, Tarceva and Oxaliplatin followed by chemotherapy with Tarceva and Gemcitabine in patients with pancreatic adenocarcinoma with borderline resectability.
- Trial name
- NCT01531712
- Testing
- Gemcitabine, Radiotherapy, Tarceva
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Institut Català d'Oncologia
Pancreatic Cancer
The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.
To investigate the correlation between pretreatment ADC value of diffusion MRI and pathologic response in patients with borderline resectable pancreatic carcinoma who undergo neoadjuvant therapy.
- Trial name
- DIFFERENT (NCT02777463)
- Testing
- diffusion-weighted MRI
- Where
- Japan
- Volunteers
- 28 people
- Sponsor
- Wakayama Medical University
Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Pancreatic Cancer
This phase I trial studies the side effects of losartan and hypofractionated radiation therapy after chemotherapy in treating patients with pancreatic cancer that may or may not be removed by surgery (borderline resectable) or…
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
- Trial name
- SHAPER (NCT04106856)
- Testing
- Hypofractionated Radiation Therapy, Losartan, Losartan Potassium
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Utah